Free tool
FAERS Monitor: Symtuza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210455 or its brand name (Symtuza, Cobicistat, Darunavir, Emtricitabine, Tenofovir Alafenamide Fumarate). Reports on generic versions are filed under their own applications.
Reports
2,754
Serious
2,063
75% of reports
Hospitalization
310
Death reported
110
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bone density decreased1,067
- bone loss609
- osteonecrosis608
- chronic kidney disease578
- tooth loss565
- multiple fractures529
- renal failure509
- osteoporosis433
- renal injury426
- skeletal injury373
- pain368
- emotional distress353
- anxiety334
- anhedonia317
- osteopenia247
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2018 | 31 |
| 2019 | 302 |
| 2020 | 942 |
| 2021 | 418 |
| 2022 | 337 |
| 2023 | 271 |
| 2024 | 224 |
| 2025 | 156 |
| 2026 | 72 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,405 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone lossSignal | 609 | 322.4 | 300.0 | 187,055 |
| skeletal injurySignal | 373 | 285.7 | 259.5 | 101,791 |
| bone density decreasedSignal | 1,067 | 269.2 | 256.5 | 275,554 |
| multiple fracturesSignal | 529 | 254.1 | 235.0 | 128,917 |
| tooth lossSignal | 565 | 213.9 | 198.5 | 116,380 |
| osteonecrosisSignal | 608 | 144.0 | 134.1 | 84,745 |
| osteopeniaSignal | 247 | 126.4 | 112.1 | 30,116 |
| renal injurySignal | 426 | 111.1 | 101.7 | 45,761 |
| anhedoniaSignal | 317 | 93.2 | 84.0 | 28,520 |
| osteoporosisSignal | 433 | 81.2 | 74.5 | 33,944 |
| chronic kidney diseaseSignal | 578 | 58.5 | 54.4 | 32,499 |
| renal failureSignal | 509 | 29.4 | 27.2 | 13,961 |
| emotional distressSignal | 353 | 22.3 | 20.3 | 7,192 |
| anxietySignal | 334 | 9.0 | 8.1 | 2,388 |
| painSignal | 368 | 4.6 | 4.2 | 1,056 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.